|View printer-friendly version|
|Medtronic to Unveil Data Supporting Endovascular Treatments for Aortic Disease at VEITHsymposium 2016|
DUBLIN - Nov. 14, 2016 - Medtronic plc (NYSE: MDT) today announced notable presentations of clinical studies on how endovascular treatments are furthering the treatment of core and complex aortic disease at the 43rd Annual Symposium of Vascular and Endovascular Issues (VEITHsymposium), the world's largest educational meeting specializing in vascular surgical medicine in New York from November 14 - 19, 2016.
This year, Medtronic's aortic technologies will be featured in more than 30 presentations at VEITHsymposium, including new data from the ENGAGE Global Registry, the ANCHOR registry and on the Valiant(TM) Captivia(TM) system to treat dissections. Additional presentations highlighting investigational technology from Medtronic, including the Valiant(TM) Mona LSA(TM), Valiant(TM)EVO thoracic stent graft system, Valiant® TAAA stent graft system and the Valiant ascending stent graft will occur throughout the symposium. A presentation on the chimney technique for endovascular aortic repair (ChEVAR) will also take place and include data from the PROTAGORAS study. This publication looked at a standardized use of the Endurant(TM) II/IIs stent graft system with ChEVAR.*
"Medtronic's Aortic business collaborates closely with physicians to provide meaningful clinical data to advance treatments for aortic disease," said Daveen Chopra, vice president and general manager of the Aortic business in Medtronic's Aortic & Peripheral Vascular division. "The breadth of data being presented at VEITHsymposium is further proof of our investment in innovation for the endovascular treatment of complex aortic disease."
Notably, new sub-set analyses from the ENGAGE Global Registry will be unveiled on Tuesday, November 15 in several sessions focused on the benefits of endovascular aortic repair (EVAR) in patients with hostile necks. In these sessions, Prof. Hence Verhagen, M.D., Ph.D., chief of vascular surgery at Erasmus Medical Center in Rotterdam, the Netherlands will present a new analysis on the safety and durability of EVAR in hostile necks, and make a second presentation on long-term outcomes in patients with complex anatomies, such as angled necks, conical necks and necks with circumferential thrombus/calcium. A complementary presentation by Prof. Dittmar Böckler, M.D., University of Heidelberg, Department of Vascular Surgery in Germany will highlight data first presented at Charing Cross on the benefit of new generation EVAR devices over first generation EVAR devices.
Another key set of presentations on Thursday, November 17 will include new findings from Medtronic's ANCHOR registry - a global, multi-center, multi-arm, prospective, post-market registry evaluating the real-world applicability of the Heli-FX(TM) EndoAnchor(TM) system in up to 2,000 patients. In a series of three presentations, researchers will present new data on the use of EndoAnchor implants in patients with complex aortic abdominal aneurysm (AAA) anatomy, particularly those who have hostile characteristics.
A schedule of key presentations appears below in chronological order in Eastern Standard Time. Some of the titles included in the presentations below may include investigational devices or uses.
Tuesday, November 15
Thursday, November 17, 2016
In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.
* In the U.S., the Endurant II/IIs stent system is approved for neck lengths >=10 mm and <=60° infra-renal angulation and it is not approved for use in chEVAR procedures .
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.